A randomized trial out of the University of Miami suggests a GLP-1 drug may give catheter ablation a serious assist. When liraglutide was added to a structured pre-ablation risk factor program, 81% of patients were free of atrial fibrillation or atrial flutter at 12 months, compared with 54% in the risk factor program alone. The size of the gap surprised investigators and has them looking beyond simple weight loss for an explanation.
Study design and results
The Liraglutide Effects in Atrial Fibrillation (LEAF) trial was a randomized, single-center study that enrolled 59 adults with a body mass index of at least 27 kg/m², about 80% of whom had persistent AFib. Participants were assigned either to a nurse-led risk factor modification (RFM) program alone or to the same program plus liraglutide for at least three months before catheter ablation. After ablation, patients were followed with long-term rhythm monitoring and cardiac imaging. At one year, the liraglutide arm showed markedly higher freedom from recurrent AF or atrial flutter, according to JACC: Clinical Electrophysiology. The trial was presented at the American College of Cardiology, and the paper is available online in the journal.
Not just weight loss
Investigators reported that both groups had only modest weight loss and similar reductions in epicardial fat volume, yet their rhythm outcomes diverged. Improvements lined up more closely with changes in epicardial fat density than with its size, suggesting metabolic or inflammatory shifts in the fat that sits on the heart. “Our findings were surprising,” study leader Dr. Jeffrey Goldberger said, noting that the magnitude of benefit exceeded expectations but that the trial was small. The University of Miami has described the results as hypothesis-generating and has called for larger, multicenter randomized trials before anyone considers routine adoption, according to University of Miami Miller School of Medicine.
How this fits into the evidence
LEAF adds to a growing body of observational and registry analyses suggesting that GLP-1 receptor agonists may reduce AF-related events and improve post-ablation outcomes, although most of that evidence is still nonrandomized. Cardiology coverage has framed the signal as promising but preliminary. Reporting on TRANSFORM-AF and similar analyses has highlighted lower AF-related events among GLP-1 users while urging randomized confirmation, as noted by TCTMD. Recent reviews have also explored epicardial adipose tissue as a metabolic target for AF. Larger randomized trials will be needed to sort out whether the benefit is specific to liraglutide, shared across the GLP-1 class, or tied to factors such as timing and dose.
What it means for Miami patients
For Miami patients, LEAF puts local researchers near the front of the line in testing metabolic strategies to improve ablation success, but the message from clinicians is still one of caution. Liraglutide is not a standard pre-ablation therapy. Access and insurance coverage for GLP-1 medications vary widely and can be costly, as insurers across the country wrestle with coverage decisions. Local reporting has captured both the excitement and the caveats around the study, as covered by CBS Miami and by coverage of payer policies on GLP-1s. For now, the LEAF team and outside experts say the next step is clear: larger, multicenter randomized trials to confirm the finding and to guide clinical practice.
